|
摘要：
|
|
摘要：目的 探讨人参皂苷Rh2制剂对于代谢相关脂肪性肝病（metabolic associated fatty
liver diseases，MAFLD）患者肝脏脂肪变的改善作用。方法 纳入2020年6月至2020年12月
期间于首都医科大学附属北京地坛医院与盐城市大丰区第三人民医院就诊的34例MAFLD
患者，根据患者意愿分为Rh2组与对照组。对照组患者（17例）给予MAFLD常规饮食运
动管理及酌情保肝治疗，Rh2组患者（17例）在常规治疗基础上联合人参皂苷Rh2制剂治
疗。采用独立样本t检验或Wilcoxon秩和检验评价治疗3个月患者肝脏弹性检查受控衰减指
数（controlled attenuation parameter，CAP）及肝脏硬度测定（liver stiffness measurement，
LSM）值下降情况。结果 纳入的34例MAFLD患者中男性20例，女性14例，年龄
（43.9 ± 14.9）岁，Rh2组患者基线CAP值显著高于对照组 [（299.7 ± 26.7）dB/m vs
（278.4 ± 32.5）dB/m；t = 2.095，P = 0.044]。治疗3个月后，Rh2组患者CAP值下降（中
位数：27.0 dB/m vs 2.0 dB/m）和LSM值下降（中位数：3.2 kPa vs 0.4 kPa）均显著优于
对照组（T = 364.5，P = 0.021；T = 398.5，P ＜ 0.001）。结论 初步证据提示MAFLD患
者在常规治疗基础上联合人参皂苷Rh2治疗有助于进一步改善肝脏脂肪变，尚需扩大样
本量、延长疗程评价人参皂苷Rh2对MAFLD患者的疗效。
|
|
Abstract: Objective To investigate the efficacy of ginsenoside Rh2 on liver steatosis of
patients with metabolic associated fatty liver diseases (MAFLD). Methods A total of 34
patients with MAFLD in Beijing Ditan Hospital, Capital Medical University and Third
People’s Hospital of Dafeng District from June 2020 to December 2020 were prospectively
enrolled. Patients were divided into Rh2 group and control group according to their
preference. Patients in control group (17 cases) were given lifestyle and exercise instruction
and liver protection agents when necessary. Patients in Rh2 group (17 cases) were given
ginsenoside Rh2 therapy addictively. The decrease of controlled attenuation parameter (CAP)
value and liver stiffness measurement (LSM) value of patients in 3 months after treatment
were evaluated by independent-sample t test or Wilcoxon rank-sum test. Results There were
20 males and 14 females out of the 34 MAFLD patients enrolled in this study. The average
age was (43.9 ± 14.9) years old. The baseline CAP value of patients in Rh2 group was
significantly higher than that of control group [(299.7 ± 26.7) dB/m vs (278.4 ± 32.5) dB/m; t =
2.095, P = 0.044]. After 3 months’ treatment, the decrease value of CAP (median: 27.0 dB/m
vs 2.0 dB/m) and LSM (median: 3.2 kPa vs 0.4 kPa) of patients in Rh2 group were significantly
better than those of control group (T = 364.5, P = 0.021; T = 398.5, P ＜ 0.001). Conclusion
Preliminary data suggested that the combination use of ginsenoside Rh2 on the basis of routine
treatment might help alleviating liver steatosis of patients with MAFLD. Further studies are in
process to verify this result with larger sample size and longer treatment duration.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|